guest ::
| Home > Publications database > Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy. > print |
| Home > Publications database > Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy. > print |
| 001 | 294754 | ||
| 005 | 20241212083138.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ccell.2024.10.008 |2 doi |
| 024 | 7 | _ | |a pmid:39515328 |2 pmid |
| 024 | 7 | _ | |a 1535-6108 |2 ISSN |
| 024 | 7 | _ | |a 1878-3686 |2 ISSN |
| 024 | 7 | _ | |a altmetric:170170874 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-02469 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Yang, Chen |0 P:(DE-He78)8b693edfb7c78bb156cc92812eec1c55 |b 0 |e First author |
| 245 | _ | _ | |a Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy. |
| 260 | _ | _ | |a New York, NY |c 2024 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1733988647_7696 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:D250# /2024 Dec 9;42(12):2064-2081.e19 |
| 520 | _ | _ | |a Tumor-initiating cells (TICs) possess the ability to evade anti-tumor immunity, potentially explaining many failures of cancer immunotherapy. Here, we identify CD49f as a prominent marker for discerning TICs in hepatocellular carcinoma (HCC), outperforming other commonly used TIC markers. CD49f-high TICs specifically recruit tumor-promoting neutrophils via the CXCL2-CXCR2 axis and create an immunosuppressive milieu in the tumor microenvironment (TME). Reciprocally, the neutrophils reprogram nearby tumor cells toward a TIC phenotype via secreting CCL4. These cells can evade CD8+ T cell-mediated killing through CCL4/STAT3-induced and CD49f-stabilized CD155 expression. Notably, while aberrant CD155 expression contributes to immune suppression, it also represents a TIC-specific vulnerability. We demonstrate that either CD155 deletion or antibody blockade significantly enhances sensitivity to anti-PD-1 therapy in preclinical HCC models. Our findings reveal a new mechanism of tumor immune evasion and provide a rationale for combining CD155 blockade with anti-PD-1/PD-L1 therapy in HCC. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a CITE-seq |2 Other |
| 650 | _ | 7 | |a hepatocellular carcinoma |2 Other |
| 650 | _ | 7 | |a immunotherapy |2 Other |
| 650 | _ | 7 | |a tumor-associated neutrophils |2 Other |
| 650 | _ | 7 | |a tumor-initiating cells |2 Other |
| 700 | 1 | _ | |a Geng, Haigang |b 1 |
| 700 | 1 | _ | |a Yang, Xupeng |b 2 |
| 700 | 1 | _ | |a Ji, Shuyi |b 3 |
| 700 | 1 | _ | |a Liu, Zhicheng |b 4 |
| 700 | 1 | _ | |a Feng, Hao |b 5 |
| 700 | 1 | _ | |a Li, Qian |b 6 |
| 700 | 1 | _ | |a Zhang, Tangansu |b 7 |
| 700 | 1 | _ | |a Zhang, Sisi |b 8 |
| 700 | 1 | _ | |a Ma, Xuhui |b 9 |
| 700 | 1 | _ | |a Zhu, Chuchen |b 10 |
| 700 | 1 | _ | |a Xu, Nuo |b 11 |
| 700 | 1 | _ | |a Xia, Yuhan |b 12 |
| 700 | 1 | _ | |a Li, Yan |b 13 |
| 700 | 1 | _ | |a Wang, Hongye |b 14 |
| 700 | 1 | _ | |a Yu, Chune |b 15 |
| 700 | 1 | _ | |a Du, Shangce |0 P:(DE-He78)842f32f9066384840481c90552ab2cff |b 16 |u dkfz |
| 700 | 1 | _ | |a Miao, Beiping |0 P:(DE-He78)b5b786a7a28d851956ba90aa9451887a |b 17 |u dkfz |
| 700 | 1 | _ | |a Xu, Lei |b 18 |
| 700 | 1 | _ | |a Wang, Hui |b 19 |
| 700 | 1 | _ | |a Cao, Ying |b 20 |
| 700 | 1 | _ | |a Li, Botai |b 21 |
| 700 | 1 | _ | |a Zhu, Lili |b 22 |
| 700 | 1 | _ | |a Tang, Xiangyu |b 23 |
| 700 | 1 | _ | |a Zhang, Haoyu |b 24 |
| 700 | 1 | _ | |a Zhu, Chunchao |b 25 |
| 700 | 1 | _ | |a Huang, Zhao |b 26 |
| 700 | 1 | _ | |a Leng, Chao |b 27 |
| 700 | 1 | _ | |a Hu, Haiyan |b 28 |
| 700 | 1 | _ | |a Chen, Xiaoping |b 29 |
| 700 | 1 | _ | |a Yuan, Shengxian |b 30 |
| 700 | 1 | _ | |a Jin, Guangzhi |b 31 |
| 700 | 1 | _ | |a Bernards, René |b 32 |
| 700 | 1 | _ | |a Sun, Chong |0 P:(DE-He78)ef40d75e5564c492ee57b4262fc016fe |b 33 |u dkfz |
| 700 | 1 | _ | |a Zheng, Quan |b 34 |
| 700 | 1 | _ | |a Qin, Wenxin |b 35 |
| 700 | 1 | _ | |a Gao, Qiang |b 36 |
| 700 | 1 | _ | |a Wang, Cun |b 37 |
| 773 | _ | _ | |a 10.1016/j.ccell.2024.10.008 |g p. S1535610824003969 |0 PERI:(DE-600)2074034-7 |n 12 |p 2064-2081.e19 |t Cancer cell |v 42 |y 2024 |x 1535-6108 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:294754 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)8b693edfb7c78bb156cc92812eec1c55 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)842f32f9066384840481c90552ab2cff |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 17 |6 P:(DE-He78)b5b786a7a28d851956ba90aa9451887a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 33 |6 P:(DE-He78)ef40d75e5564c492ee57b4262fc016fe |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER CELL : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-24 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-24 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-24 |
| 915 | _ | _ | |a IF >= 50 |0 StatID:(DE-HGF)9950 |2 StatID |b CANCER CELL : 2022 |d 2023-10-24 |
| 920 | 1 | _ | |0 I:(DE-He78)D250-20160331 |k D250 |l NWG Krebs-Immunregulation |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)D250-20160331 |k D250 |l NWG Krebs-Immunregulation |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D250-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|